Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Cardiac Marker Testing Market analysis
Part of: Cardiac Marker Testing Market (Global)

The Japan Cardiac Marker Testing Market was valued at $136.8 Million in 2026 and projected to reach to $247.8 Million by 2031, representing a compound annual growth rate of 12.6%. Japan's cardiac marker testing market is positioned for sustained expansion through 2031, driven by the convergence of demographic shifts and technological advancement.

Japan Cardiac Marker Testing Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Cardiac Marker Testing Market Trends and Insights

  • Japan's aging population and rising prevalence of cardiovascular diseases are driving demand for advanced diagnostic testing solutions.
  • The market in Japan benefits from strong healthcare infrastructure, high adoption of point-of-care testing technologies, and increasing awareness of early cardiac disease detection among healthcare providers and patients. The cardiac marker testing sector in Japan is characterized by significant investment in laboratory automation and digital health integration.
  • Japan's emphasis on precision medicine and preventive healthcare is accelerating the adoption of high-sensitivity troponin assays and multiplex cardiac biomarker panels.
  • Regulatory support from Japan's health authorities and reimbursement policies favorable to cardiac diagnostics are further propelling market expansion through 2031..

Key Market Statistics

  • CAGR (2026-2031) 12.6% CAGR
  • Market Size, 2026 ~USD 136.8 Million
  • Forecast, 2031 ~USD 247.8 Million
  • Country Japan

Japan Cardiac Marker Testing Market Overview

Aging Population Driving Demand :

Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly increasing the prevalence of cardiovascular diseases and creating sustained demand for cardiac marker testing solutions.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system and high healthcare spending per capita enable rapid adoption of cutting-edge diagnostic technologies and point-of-care testing platforms for cardiac markers.

Strong POCT Adoption :

Japanese hospitals and clinics demonstrate exceptional adoption rates for point-of-care cardiac testing, driven by the need for rapid diagnosis and the country's emphasis on preventive healthcare.

Robust Market Growth Trajectory :

The Japanese cardiac marker testing market is projected to grow from USD 136.8 million in 2026 to USD 247.8 million by 2031, representing a 12.6% CAGR, outpacing the global average of 10.3%.

Japan Cardiac Marker Testing Market Dynamics

  • The country's aging population, combined with increasing cardiovascular disease incidence, creates a structural demand tailwind for diagnostic testing solutions.
  • Healthcare providers are increasingly investing in rapid diagnostic capabilities to improve patient outcomes and reduce hospital readmission rates. The market will be further supported by Japan's commitment to healthcare innovation and the integration of digital health technologies.
  • Regulatory support for advanced diagnostics, coupled with strong reimbursement policies, will facilitate market penetration of novel cardiac biomarker assays.
  • Strategic partnerships between domestic and international diagnostic manufacturers will accelerate product launches and market expansion across Japan's urban and regional healthcare networks..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
    Top Companies

      Medical Devices

      Top Technologies
        Top Companies

          Key Takeaways

          • Japan's cardiac marker testing market will grow from USD 136.8M (2026) to USD 247.8M (2031), representing a 12.6% CAGR.
          • Japan's aging demographic and high cardiovascular disease burden are primary drivers of market expansion.
          • Japan leads in adoption of high-sensitivity troponin and multiplex biomarker testing technologies.
          • Japan's favorable reimbursement environment and regulatory framework support sustained market growth through 2031.

          Cardiac Marker Testing Market Report Scope

          Report Metric Details
          Base Year 2026
          Fastest Growing Segment OTHER CARDIAC BIOMARKERS (Biomarker Type)
          Forecast Period 2026–2031
          Growth Rate CAGR of 10.3% from 2026 to 2031
          Largest Segment SINGLEPLEX ASSAY (Assay Format)
          Market Size Base Year (Billions) ~USD 5.55 (2026)
          Revenue Forecast (Billions) ~USD 9.06 (2031)
          Segments Covered Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User

          Japan Cardiac Marker Testing Market Report Segmentation

          8 segment dimensions are covered across the global market.

          By Product

          • Instruments
          • Reagents & Kits

          By Technology

          • Clinical Chemistry
          • Immunoassay
          • Immunoassays

          By Type

          • Chemiluminescence
          • Contract Testing Laboratories
          • Elisa
          • Hospital Laboratories
          • Immunofluorescence
          • Lateral Flow Immunoassay
          • Reference Laboratories

          By Indication

          • Acute Coronary Syndrome
          • Atherosclerosis
          • Congestive Heart Failure
          • Ischemia
          • Myocardial Infarction

          By Biomarker Type

          • Brain Natriuretic Peptide
          • Creatinine Kinase-Mb
          • High-Sensitivity C-Reactive Protein
          • Homocysteine
          • Myoglobin
          • Other Cardiac Biomarkers
          • Troponin I & T

          By Point Of Testing

          • Lab Tests
          • Poc Tests

          By Assay Format

          • Multiplex Assay
          • Multiplex Assays
          • Singleplex Assay
          • Singleplex Assays

          By End User

          • Academic Institutes
          • Laboratory Testing Facilities
          • Point-Of-Care Testing

          JAPAN: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031

          Segment20242025202620272028202920302031CAGR (%)
          ACADEMIC INSTITUTES24.625.728.832.236.140.645.651.212.2
          LABORATORY TESTING FACILITIES115.2119.2132.1146.2162.1179.9199.9221.810.9
          POINT-OF-CARE TESTING5052.859.767.576.586.798.5111.713.3
          TOTAL189.7197.6220.6246274.7307.2344384.711.8

          Target Audience

          • In Vitro Diagnostics Manufacturers : IVD companies seeking to expand their cardiac marker testing portfolio in Japan need detailed market intelligence to identify growth opportunities, assess competitive positioning, and optimize product development strategies for this high-growth market.
          • Hospital & Clinical Laboratory Administrators : Japanese healthcare facility leaders require market data to benchmark their cardiac testing capabilities, evaluate emerging diagnostic technologies, and make informed procurement decisions aligned with market trends.
          • Medical Device Distributors & Importers : Japan-based distributors need country-specific market insights to identify high-potential cardiac marker testing products, forecast demand, and develop effective sales strategies for their customer base.
          • Healthcare Investment & Private Equity Firms : Investors evaluating opportunities in Japan's healthcare diagnostics sector require comprehensive market data to assess investment returns, identify acquisition targets, and understand growth trajectories in cardiac testing.
          • Healthcare Policy & Government Agencies : Japanese health ministry officials and policy makers need market intelligence to inform healthcare infrastructure planning, reimbursement policy development, and strategic initiatives supporting cardiovascular disease management.

          Key Companies in the Japan Cardiac Marker Testing Market

          CompanyHQOwnershipStrongest segments
          ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
          DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software),
          SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
          THERMO FISHER SCIENTIFICUnited StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
          BIO-RAD LABORATORIESUnited StatesPublic CompanyLife Science,Clinical Diagnostics,
          BIOMéRIEUX SAFrancePublic CompanyClinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA),
          BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
          DIASORIN SPAItalyPublic CompanyImmunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory,
          REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software,
          TOSOH CORPORATIONJapanPublic CompanyBasic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins),
          QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care,
          GUANGZHOU WONDFO BIOTECH CO., LTD.ChinaPublic CompanyRapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform,

          ABBOTT LABORATORIES

          Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.

          DANAHER CORPORATION

          Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.

          SIEMENS HEALTHINEERS AG

          Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.

          THERMO FISHER SCIENTIFIC

          Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

          BIO-RAD LABORATORIES

          Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.

          BIOMéRIEUX SA

          bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.

          BECTON, DICKINSON AND COMPANY

          Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.

          DIASORIN SPA

          DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.

          REVVITY

          Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

          TOSOH CORPORATION

          Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.

          QUIDEL CORPORATION

          Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.

          GUANGZHOU WONDFO BIOTECH CO., LTD.

          Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.

          Reasons to Buy this Report

          • Japan-Specific Market Sizing : Access precise market valuations and forecasts tailored exclusively to Japan, enabling accurate budget allocation and revenue projections for market entry or expansion strategies in this high-value healthcare market.
          • Competitive Landscape Intelligence : Understand the competitive dynamics specific to Japan's cardiac marker testing sector, including local and international player positioning, market share distribution, and differentiation strategies.
          • Regulatory & Reimbursement Insights : Gain detailed knowledge of Japan's unique regulatory framework, reimbursement policies, and healthcare system requirements that directly impact product approval timelines and market accessibility.
          • Growth Driver Analysis : Identify Japan-specific growth catalysts including demographic trends, healthcare infrastructure investments, and technology adoption patterns that will shape market opportunities through 2031.
          • Strategic Market Entry Guidance : Leverage Japan-focused insights to develop targeted go-to-market strategies, identify key distribution channels, and prioritize customer segments within Japan's fragmented healthcare ecosystem.

          Frequently asked questions

          What is the current size of Japan's cardiac marker testing market?

          Japan's cardiac marker testing market is valued at USD 136.8 million in 2026 and is expected to reach USD 247.8 million by 2031.

          What is the projected growth rate for Japan's cardiac marker testing market?

          Japan's cardiac marker testing market is projected to grow at a compound annual growth rate (CAGR) of 12.6% from 2026 to 2031.

          What factors are driving growth in Japan's cardiac marker testing market?

          Key drivers include Japan's aging population, rising cardiovascular disease prevalence, advanced healthcare infrastructure, adoption of point-of-care testing, and favorable reimbursement policies.

          Which cardiac marker tests are most commonly used in Japan?

          Japan shows strong adoption of high-sensitivity troponin assays and multiplex cardiac biomarker panels as part of its precision medicine approach.

          How does Japan's regulatory environment support cardiac marker testing?

          Japan's health authorities provide regulatory support and favorable reimbursement policies that encourage adoption of advanced cardiac diagnostic technologies.

          RESEARCH METHODOLOGY

          The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.

          Secondary Research

          In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

          Primary Research

          In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

          BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS

          Cardiac Marker Testing Market Size, and Share

          Note 1: Others include sales managers, marketing managers, and product managers.
          Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

          COMPANY NAME

          DESIGNATION

          Abbott Laboratories (US)

          Sales Manager

          F. Hoffmann-La Roche AG (Switzerland)

          Product Manager

          To know about the assumptions considered for the study, download the pdf brochure

          Market Size Estimation

          Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:

          • The key players in the industry have been identified through extensive secondary research
          • The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
          • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

          The research methodology used to estimate the market size includes the following:

          Cardiac Marker Testing Market Top Down and Bottom Up Approach

          Data Triangulation

          After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

          Market Definition

          Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).

          Key Stakeholders

          • Product Manufacturers, Distributors, and Suppliers
          • Diagnostic Laboratories and Point-of-care Testing Centers
          • Research Laboratories and CROs
          • Ambulatory Testing Centers
          • Contract Testing Laboratories
          • Academic Universities and Medical Research Centers
          • Research & Development (R&D) Centers

          Report Objectives

          • To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
          • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
          • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
          • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
          • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
          • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
          • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
          • To study the impact of AI on the market, along with the macroeconomic outlook for each region

          Available customizations:

          MarketsandMarkets offers the following customizations for this market report.

          Country Information

          • Additional country-level analysis of the cardiac marker testing market

          Company profiles

          • Additional five company profiles of players operating in the cardiac marker testing market.

          Product Analysis

          • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market

           

          Get the Full Cardiac Marker Testing Market Report

          Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.

          Download Sample Pages Buy Report

          METHODOLOGY

          Need a Tailored Report?

          Customize this report to your needs

          Get 10% FREE Customization

          Customize This Report
          Fact checked
          Cite this Research
          DMCA.com Protection Status